New Clues with Omalizumab for Broncho-Cutaneous Hyperresposiveness

 We retrospectively retrieved our records and identified Five patients who had used Omalizumab due to allergic asthma and co-existent physical urticaria. Patients received Omalizumab at a dose of 150 to 300 mg/month for 16 weeks. DLQI was measured before and after  three months of Omalizumab treatment. The beneficial effects of anti-IgE treatment observed in both allergic asthma and physical urticaria, as seen in our cases, suggests Ig E as a potential actor in the pathogenesis these disorders.